Triera Biosciences

Triera Biosciences Logo

Zentek and Triera Biosciences Ltd. Achieve Positive Results Against Avian Influenza (H5N1) using Multivalent Aptamer Technology

Guelph, ON – May 6, 2024, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. (“Triera”) has prioritized the development of a prophylaxis and therapeutic for highly pathogenic avian influenza (“HPAI”) and reports initial test results. Background and Highlights: Universal aptamer Read more…

Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA

Guelph, ON – March 25, 2024, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. (“Triera”) has completed testing demonstrating that its C19HBA SARS-CoV-2 universal aptamer built on the proprietary high-binding affinity aptamer platform has shown a promising safety and toxicity Read more…